Women's Malignancies Branch
Christina M. Annunziata has not added Biography.
If you are Christina M. Annunziata and would like to personalize this page please email our Author Liaison for assistance.
Is there a genomic basis for primary chemoresistance in ovarian cancer?
Gynecologic oncology Jul, 2003 | Pubmed ID: 12821333
Proteomics in clinical trials and practice: present uses and future promise.
Molecular & cellular proteomics : MCP Oct, 2006 | Pubmed ID: 16737951
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.
Cancer cell Aug, 2007 | Pubmed ID: 17692804
BAG-4/SODD and associated antiapoptotic proteins are linked to aggressiveness of epithelial ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research Nov, 2007 | Pubmed ID: 18006758
Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy.
Cancer Apr, 2008 | Pubmed ID: 18300236
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Aug, 2008 | Pubmed ID: 18669456
Uterine papillary serous carcinoma: a new paradigm for treatment?
Cancer Aug, 2009 | Pubmed ID: 19452535
The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome.
Blood Apr, 2010 | Pubmed ID: 19965618
Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.
Clinical cancer research : an official journal of the American Association for Cancer Research Jan, 2010 | Pubmed ID: 20068097
Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer.
Cancer research May, 2010 | Pubmed ID: 20424119
Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer.
Cancer Jul, 2010 | Pubmed ID: 20564628
CD157 in ovarian carcinoma: how does it help us?
Journal of the National Cancer Institute Aug, 2010 | Pubmed ID: 20639477
Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research Sep, 2010 | Pubmed ID: 20823142
PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer.
F1000 biology reports , 2010 | Pubmed ID: 20948822
A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression.
Blood Feb, 2011 | Pubmed ID: 21163924
Targeting the proteasome with bortezomib in multiple myeloma: update on therapeutic benefit as an upfront single agent, induction regimen for stem-cell transplantation and as maintenance therapy.
American journal of therapeutics Mar, 2012 | Pubmed ID: 21248621
Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors.
Investigational new drugs Feb, 2012 | Pubmed ID: 22370972
IKK-ε coordinates invasion and metastasis of ovarian cancer.
Cancer research Nov, 2012 | Pubmed ID: 22942254
Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells.
Proceedings of the National Academy of Sciences of the United States of America Dec, 2012 | Pubmed ID: 23236152
Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort.
Molecular & cellular proteomics : MCP Jun, 2013 | Pubmed ID: 23449826
Novel facts about FAK: new connections to drug resistance?
Journal of the National Cancer Institute Oct, 2013 | Pubmed ID: 24062526
A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety.
Molecular and clinical oncology May, 2013 | Pubmed ID: 24649212
Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer.
PloS one , 2014 | Pubmed ID: 24748377
Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.
Journal of the National Cancer Institute Jun, 2014 | Pubmed ID: 24842883
The small molecule NSC676914A is cytotoxic and differentially affects NFκB signaling in ovarian cancer cells and HEK293 cells.
Cancer cell international , 2014 | Pubmed ID: 25324692
Loss of compensatory pro-survival and anti-apoptotic modulator, IKKε, sensitizes ovarian cancer cells to CHEK1 loss through an increased level of p21.
Oncotarget Dec, 2014 | Pubmed ID: 25474241
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved